Abstract Mesoporous carbon nanoparticles (MCNs) have been widely used in tumor photothermal therapy. Herein, MCNs with different particle sizes (100 nm, 400 nm and 500 nm) were fabricated in our work by controlling the ethanol amounts to evaluate their photothermal conversion performance. Rationally, small-sized MCNs with the highest photothermal conversion efficiency were selected as the drug-loading carriers. Subsequently, the spherical gold nanoparticles with the same size (4 nm) as the mesopores of MCNs were modified on the opening of MCNs as the gated switches, which could not only achieve the redox-responsive controlled release of anticancer drugs at tumor location, but also realize the photothermal-enhanced synergetic thermochemotherapy under a low power irradiation. Meanwhile, the photothermal conversion efficiency (η) of MCN-Au was 31.2 %, which was higher than that of MCNs (η = 28.3 %). DOX release increased significantly under the condition of high concentration of GSH, low pH and NIR, suggesting that the delivery platform was characterized by multi-responsive drug release. In addition, the combined therapeutic index of DOX/MCN-Au was 0.509, proving that the combination group of thermochemotherapy had the highest cell killing ability. Meanwhile, confocal laser scanning microscopy (CLSM) showed that DOX/MCN-Au had an increased cellular uptake efficiency under NIR irradiation. In summary, the constructed DOX/MCN-Au system was expected to show a clinical treatment potential for synergistic thermochemotherapy of tumors.

中文翻译：

---

具有最佳粒径的金纳米粒子门控介孔碳用于光热增强热化学疗法

摘要 介孔碳纳米粒子（MCNs）已广泛应用于肿瘤光热治疗。在此，我们通过控制乙醇的用量制备了不同粒径（100 nm、400 nm 和 500 nm）的 MCN，以评估其光热转换性能。合理地选择具有最高光热转换效率的小尺寸 MCN 作为载药载体。随后，在作为门控开关的 MCNs 开口处修饰了与 MCNs 介孔相同尺寸（4 nm）的球形金纳米粒子，不仅可以实现抗癌药物在肿瘤位置的氧化还原响应控制释放，而且还实现了低功率照射下的光热增强协同热化学疗法。同时，MCN-Au的光热转换效率（η）为31.2%，高于 MCN（η = 28.3 %）。在高浓度 GSH、低 pH 和 NIR 条件下，DOX 释放显着增加，表明该递送平台具有多响应药物释放的特点。此外，DOX/MCN-Au的联合治疗指数为0.509，证明热化疗联合组的细胞杀伤能力最高。同时，共聚焦激光扫描显微镜 (CLSM) 显示 DOX/MCN-Au 在 NIR 照射下具有增加的细胞摄取效率。总之，构建的 DOX/MCN-Au 系统有望显示出用于肿瘤协同热化学疗法的临床治疗潜力。表明递送平台的特点是多响应药物释放。此外，DOX/MCN-Au的联合治疗指数为0.509，证明热化疗联合组的细胞杀伤能力最高。同时，共聚焦激光扫描显微镜 (CLSM) 显示 DOX/MCN-Au 在 NIR 照射下具有增加的细胞摄取效率。总之，构建的 DOX/MCN-Au 系统有望显示出用于肿瘤协同热化学疗法的临床治疗潜力。表明递送平台的特点是多响应药物释放。此外，DOX/MCN-Au的联合治疗指数为0.509，证明热化疗联合组的细胞杀伤能力最高。同时，共聚焦激光扫描显微镜 (CLSM) 显示 DOX/MCN-Au 在 NIR 照射下具有增加的细胞摄取效率。总之，构建的 DOX/MCN-Au 系统有望显示出用于肿瘤协同热化学疗法的临床治疗潜力。共聚焦激光扫描显微镜 (CLSM) 显示 DOX/MCN-Au 在 NIR 照射下具有增加的细胞摄取效率。总之，构建的 DOX/MCN-Au 系统有望显示出用于肿瘤协同热化学疗法的临床治疗潜力。共聚焦激光扫描显微镜 (CLSM) 显示 DOX/MCN-Au 在 NIR 照射下具有增加的细胞摄取效率。总之，构建的 DOX/MCN-Au 系统有望显示出用于肿瘤协同热化学疗法的临床治疗潜力。